Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 1;2(1):e22789.
doi: 10.4161/onci.22789.

Trial watch: Monoclonal antibodies in cancer therapy

Erika Vacchelli  1 , Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Affiliations

Trial watch: Monoclonal antibodies in cancer therapy

Erika Vacchelli et al. Oncoimmunology. .

Abstract

During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction cascades, either as they specifically delivery toxins to malignant cells or as they block the tumor-stroma interaction. Such an intense research effort has lead to the approval by FDA of no less than 14 distinct molecules for use in humans affected by hematological or solid malignancies. In the inaugural issue of OncoImmunology, we briefly described the scientific rationale behind the use of monoclonal antibodies in cancer therapy and discussed recent, ongoing clinical studies investigating the safety and efficacy of this approach in patients. Here, we summarize the latest developments in this exciting area of clinical research, focusing on high impact studies that have been published during the last 15 months and clinical trials launched in the same period to investigate the therapeutic profile of promising, yet hitherto investigational, monoclonal antibodies.

Keywords: bevacizumab; dalotuzumab; ipilimumab; nimotuzumab; ramucirumab; trastuzumab.

PubMed Disclaimer

Similar articles

  • Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.
    Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2014 Jan 1;3(1):e27048. doi: 10.4161/onci.27048. Oncoimmunology. 2014. PMID: 24605265 Free PMC article. Review.
  • Trial watch: Chemotherapy with immunogenic cell death inducers.
    Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2013 Mar 1;2(3):e23510. doi: 10.4161/onci.23510. Oncoimmunology. 2013. PMID: 23687621 Free PMC article.
  • Trial Watch: Immunostimulatory cytokines.
    Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2013 Jul 1;2(7):e24850. doi: 10.4161/onci.24850. Epub 2013 May 7. Oncoimmunology. 2013. PMID: 24073369 Free PMC article. Review.
  • Trial Watch: Peptide vaccines in cancer therapy.
    Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Aranda F, et al. Oncoimmunology. 2013 Dec 1;2(12):e26621. doi: 10.4161/onci.26621. Epub 2013 Nov 4. Oncoimmunology. 2013. PMID: 24498550 Free PMC article. Review.
  • Trial Watch: Monoclonal antibodies in cancer therapy.
    Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Galluzzi L, et al. Oncoimmunology. 2012 Jan 1;1(1):28-37. doi: 10.4161/onci.1.1.17938. Oncoimmunology. 2012. PMID: 22720209 Free PMC article.
See all similar articles

Cited by

  • Classification of current anticancer immunotherapies.
    Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
  • Novel immune checkpoint blocker approved for the treatment of advanced melanoma.
    Galluzzi L, Kroemer G, Eggermont A. Galluzzi L, et al. Oncoimmunology. 2014 Dec 21;3(11):e967147. doi: 10.4161/21624011.2014.967147. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941597 Free PMC article. No abstract available.
  • Trial watch: Naked and vectored DNA-based anticancer vaccines.
    Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Bloy N, et al. Oncoimmunology. 2015 Apr 2;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155408 Free PMC article.
  • Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.
    Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, De La Rochere P, Amzallag N, Osinaga E, Oppezzo P, Pritsch O, Sastre-Garau X, Hubert P, Amigorena S, Piaggio E. Sedlik C, et al. Oncoimmunology. 2016 Apr 22;5(7):e1171434. doi: 10.1080/2162402X.2016.1171434. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622021 Free PMC article.
  • Trial Watch: Lenalidomide-based immunochemotherapy.
    Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Semeraro M, et al. Oncoimmunology. 2013 Nov 1;2(11):e26494. doi: 10.4161/onci.26494. Epub 2013 Oct 21. Oncoimmunology. 2013. PMID: 24482747 Free PMC article. Review.
See all "Cited by" articles

References

    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7. doi: 10.1038/256495a0. - DOI - PubMed
    1. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol. 2004;4:153–6. doi: 10.1038/nri1265. - DOI - PubMed
    1. Zou YR, Gu H, Rajewsky K. Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions. Science. 1993;262:1271–4. doi: 10.1126/science.8235658. - DOI - PubMed
    1. Ortho Multicenter Transplant Study Group A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985;313:337–42. doi: 10.1056/NEJM198508083130601. - DOI - PubMed
    1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27. doi: 10.1038/nri2744. - DOI - PMC - PubMed

Publication types

LinkOut - more resources